Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 32Central Nervous System Neoplasms 30Carcinoma, Non-Small-Cell Lung 28Lung Neoplasms 27Head and Neck Neoplasms 26Glioblastoma 25Leukemia 24Squamous Cell Carcinoma of Head and Neck 22Lymphoma 22Gliosarcoma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Sarcoma 17Astrocytoma 17Burkitt Lymphoma 14Pancreatic Neoplasms 13Rectal Neoplasms 12Lymphoma, Large B-Cell, Diffuse 12Uterine Cervical Neoplasms 11Neuroblastoma 11Lymphoma, Follicular 10Adenocarcinoma of Lung 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 9Leukemia, Myeloid, Acute 9Esophageal Neoplasms 9Brain Neoplasms 9Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Laryngeal Neoplasms 8Hodgkin Disease 8

Interventions

atezolizumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2talazoparib 1olaparib 1cediranib 1Radiotherapy 1Radiation 1Platinum 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡